



Jazz Pharmaceuticals Completes Sale of its Women's Health Business to Meda

October 15, 2012

DUBLIN, Oct. 15, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the sale of its women's health business to Meda (an international specialty pharmaceutical company) for \$95 million in cash.

The products included in the sale are Elestrin[®] (estradiol gel), Gastrocrom[®] (cromolyn sodium, USP), Natelle[®] One (prenatal vitamin), AVC[™] Cream (sulfanilamide), Gesticare[®] DHA (prenatal multi-vitamin) and Urelle[®] (urinary antiseptic).

For accounting purposes, the women's health business will be treated as a discontinued operation. More detail about the accounting impact of the transaction will be disclosed in pro forma financial statements filed on a Form 8-K and in the company's Form 10-Q for the quarter ended September 30, 2012.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products to meet unmet medical needs. The company's U.S. marketed products include: Xyrem[®] (sodium oxybate), Erwinaze [™] (asparaginase *Erwinia chrysanthemi*), Prialt[®] (ziconotide) intrathecal infusion, FazaClo[®] (clozapine USP) HD and LD and Luvox CR[®] (fluvoxamine maleate). Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by an international division, EUSA Pharma. For further information, see <http://www.jazzpharmaceuticals.com>.

SOURCE Jazz Pharmaceuticals plc

William Craumer, Director, Investor Relations, Jazz Pharmaceuticals, Ireland, + 353 1 6343211, U.S., +1-650-496-2947